DKK1 and esophageal squamous cell carcinoma: The measurement of either DKK‐1 or its autoantibody in our study does not seem sensitive enough (i.e., high false negative rate), with sensitivity of around 30–40% in patients with ESCC and early‐stage ESCC in the training cohort (Table 2).